coronavirus Archives - Page 93 of 99 - Medical Design Sourcing

Harvard’s Wyss Institute wants to create a COVID-19 antibody test strip

[Image courtesy of The iQ Group Global]

The iQ Group Global announced today that it has inked a collaboration with Harvard’s Wyss Institute to develop a printable point-of-care SARS-CoV-2 antibody test with real-time results.

Life Science Biosensor Diagnostics, the iQ Group’s development company, has been working on the Australian-invented Biosensor Platform, a printable organic thin-film transistor “strip” that has the potential to provide a variety of medical tests — and even potentially replace blood glucose finger stick tests for diabetics. The Wyss Institute for Biologically Inspired Engineering at Harvard University has meanwhile created a special coating that can detect IgM and/or IgG antibodies.

Get the full story on our sister site Medical Design & Outsourcing.

Harvard’s Wyss Institute wants to create a COVID-19 antibody test strip

[Image courtesy of The iQ Group Global]

The iQ Group Global announced today that it has inked a collaboration with Harvard’s Wyss Institute to develop a printable point-of-care SARS-CoV-2 antibody test with real-time results.

Life Science Biosensor Diagnostics, the iQ Group’s development company, has been working on the Australian-invented Biosensor Platform, a printable organic thin-film transistor “strip” that has the potential to provide a variety of medical tests — and even potentially replace blood glucose finger stick tests for diabetics. The Wyss Institute for Biologically Inspired Engineering at Harvard University has meanwhile created a special coating that can detect IgM and/or IgG antibodies.

A new pilot study will test the integration of the Biosensor Platform with the Wyss coating for spotting COVID-19 antibodies. The eventual goal is a chewing-gum-sized diagnostic &…

Sherlock Biosciences announces manufacturing partnership for CRISPR-based COVID-19 test

Sherlock Biosciences announced today that it will collaborate with Integrated DNA Technologies (IDT) to enable large-scale manufacturing of the Sherlock CRISPR SARS-CoV-2 kit for COVID-19 detection.

Officials at Cambridge, Mass.–based Sherlock Biosciences think the company’s CRISPR-based diagnostic test, which recently received an FDA emergency use authorization, will increase testing capacity and decreasing time to result amid the coronavirus pandemic.

Get the full story on our sister site Pharmaceutical Processing World.

MedTech 100 roundup: Stocks stand pat in June’s first week

While the markets experienced some growth over the past week, stocks in the medtech industry remained practically unchanged over seven days.

MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 87.15 points at the end of last week (June 5). That total represents just a -0.02-point decrease from the 87.17-point total at the same time a week prior (May 29), which represented the industry’s highest point since before the COVID-19 pandemic took hold of the markets.

Meanwhile, the S&P 500 Index experienced a 3.14% increase from May 29 to June 5 and the Dow Jones Index fared even better with a 6.81% increase over the same period of time. The market surge came on the back of the White House announcement that 2.5 million jobs were added in May and unemployment rose to 13.3% when a surge to nearly 20% was expected, according to Yahoo Finance.

The lowest point for medtech during the COVID-19 pand…

Clew Medical gains EUA for predictive screening software for COVID-19

Clew Medical recently received FDA emergency use authorization for its ClewICU System for use in intensive care units.

The EUA covers the company’s ClewICUServer and ClewICUnitor. The system is a standalone software that is designated as a medical device. It uses commonly recorded vital signs, nursing assessments, flowsheet data, medications and lab data to compute patient status indexes.

Data defined by the system includes CLEWRF, which is a measure of a patient’s predicted physiologic condition within the next eight hours based on the aggregate statistical risk of respiratory deterioration or failure, and CLEWHI, which is a measure of a patient’s predicted physiological condition within the next eight hours based on the aggregate statistical risk of hemodynamic instability.

The system is cleared for use in adults in ICU while treating COVID-19 as a diagnostic aid with the early identification of patients who are likely to experience r…

Cantel Medical up on Street-beating Q3

Cantel Medical (NYSE:CMD) shares ticked up today on third-quarter financial results that came in ahead of the consensus forecast.

The Little Falls, N.J.-based company posted profits of $15.8 million, or 37¢ per share, on sales of $236.9 million for the three months ended April 30, 2020, for a 93.1% bottom-line gain on sales growth of 3.7%.

Adjusted to exclude one-time items, earnings per share were 16¢, 4¢ ahead of Wall Street, where analysts were looking for sales of $235.4 million.

Cantel Medical said in a news release that a decline in organic sales came as a result of the reduction of elective procedures caused by the COVID-19 pandemic, which mostly affected the last five weeks of the third quarter. Adjusted earnings per share dropped from 55¢ in the third quarter of 2019 in a trend that was driven by the effects of the pandemic.

The company said its medical and dental segments were primarily impacted, although most impacts were offset by a fa…

NASA, Fitbit gain EUAs for COVID-19 devices

The FDA granted emergency use authorization (EUA) for emergency COVID-19 ventilator devices developed by Nasa and Fitbit (NYSE:FIT).

According to the FDA’s ongoing list of devices granted EUAs, both devices were authorized on June 1. NASA’s VITAL (ventilator intervention technology accessible locally) compressor and the Fitbit Flow are the latest of a few ventilator alternatives to garner EUA status.

NASA’s VITAL compressor is designed to offer continuous ventilatory support for adult patients requiring ventilation when no standard ventilators are available. It is a restricted device intended for use by a qualified healthcare provider.

The VITAL compressor is the second NASA ventilator to earn EUA, after the original VITAL device obtained authorization last month. NASA touts VITAL as capable of being built faster and maintained more easily than a traditional ventilator. The device includes fewer parts than other ventilators, many of whi…

Canada orders 37 million syringes from BD in anticipation of COVID-19 vaccine

Canada reportedly signed a contract to purchase 37 million syringes from Becton Dickinson (NYSE:BDX) in preparation for a potential COVID-19 vaccine.

A report in The Record revealed that Public Services & Procurement Minister Anita Anand said the country made a purchase order from the Canadian branch of BD in an effort to make sure Canada is ready for mass vaccinations if the cure for COVID-19 is discovered. There is no definitive timeline for the delivery of the syringes as of now.

Get the full story at our sister site, MassDevice.

Canada orders 37 million syringes from BD in anticipation of COVID-19 vaccine

Canada reportedly signed a contract to purchase 37 million syringes from Becton Dickinson (NYSE:BDX) in preparation for a potential COVID-19 vaccine.

A report in The Record revealed that Public Services & Procurement Minister Anita Anand said the country made a purchase order from the Canadian branch of BD in an effort to make sure Canada is ready for mass vaccinations if the cure for COVID-19 is discovered. There is no definitive timeline for the delivery of the syringes as of now.

Get the full story on our sister site MassDevice.

Canada orders 37 million syringes from BD in anticipation of COVID-19 vaccine

Canada reportedly signed a contract to purchase 37 million syringes from Becton Dickinson (NYSE:BDX) in preparation for a potential COVID-19 vaccine.

A report in The Record revealed that Public Services & Procurement Minister Anita Anand said the country made a purchase order from the Canadian branch of BD in an effort to make sure Canada is ready for mass vaccinations if the cure for COVID-19 is discovered. There is no definitive timeline for the delivery of the syringes as of now.

The Record cited Statistics Canada as reporting that more than 38 million people comprise the country’s population, one million more than the total number of syringes agreed upon in the contract. Canada Chief Public Health Officer Theresa Tam said the order represents the “maximum number of Canadians who may wish to be vaccinated,” according to the report.

Currently, Chinese pharmaceutical company CanSino Biologics is collabo…

U of M releases Coventor ventilator design as open-source

The University of Minnesota recently announced that it released the design for its Coventor alternative ventilator as open-source.

Minnesota’s Coventor low-cost device gained notoriety in March after researchers touted the design made from various parts totaling just $150. In April, it became the first ventilator of its kind authorized for use under the FDA’s EUA for the COVID-19 pandemic.

Also in April, Boston Scientific (NYSE:BSX) announced that it was sole manufacturer of the device, which the company said it expects to sell at-cost at approximately $1,000 per unit.

The Coventor is now available to companies who are interested in manufacturing it. They can sign a free electronic license and download the manufacturing specifications.

“From the outset, the mission of this project was to make this emergency device available to people in need, wherever they might be in the world, as quickly and safely as possible,” Dr. Stephen Richardson, a…

Philips wins EUA for acute-care patient monitoring

Royal Philips (NYSE:PHG) announced today that it received FDA emergency use authorization (EUA) for its IntelliVue patient monitors and active displays.

The Amsterdam-based company’s IntelliVue monitors MX750/MX850 and active displays AD75/D85 received authorization to support infection-control protocols and provide caregivers information remotely during the ongoing COVID-19 pandemic.

Both sets of IntelliVue products received CE Mark approval last year and the MX750 patient monitor already received EUA in April. The latest EUA allows Philips to begin delivering the remote monitoring products to hospitals in the U.S., while it is preparing to submit to the FDA for 510(k) clearance this year.

The monitors and active displays include Philips’ IntelliVue Horizon Trends information view that shows deviations in vital signs. It also features an alarm advisor and alarm reporting to reduce caregivers’ alarm fatigue. Philips noted in a news rele…